Decision to fund bedaquiline and linezolid for multi-drug resistant tuberculosis

+Undoctored

Decision to fund bedaquiline and linezolid for multi-drug resistant tuberculosis

Statement from Pharmac
PreviousNext
Undoctored

Pharmac will fund bedaquiline and linezolid for multi-drug resistant tuberculosis (MDR-TB) from 1 July 2023

We're pleased to announce that from 1 July 2023 bedaquiline and linezolid will be funded for multi-drug resistant tuberculosis (MDR-TB) for both community and hospital use. This change will enable people with MDR-TB to be treated in the community where appropriate.

READ MORE

 

Missing out on our email newsletters? Sign up here:

 

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please see our Privacy Statement.